Do antibody CDR loops change conformation upon binding?

ABSTRACTAntibodies have increasingly been developed as drugs with over 100 now licensed in the US or EU. During development, it is often necessary to increase or reduce the affinity of an antibody and rational attempts to do so rely on having a structure of the antibody-antigen complex often obtaine...

Full description

Saved in:
Bibliographic Details
Main Authors: Chu'nan Liu (Author), Lilian M. Denzler (Author), Oliver E.C. Hood (Author), Andrew C.R. Martin (Author)
Format: Book
Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ea0ff2b1ed564d10a991b78706b3b6b9
042 |a dc 
100 1 0 |a Chu'nan Liu  |e author 
700 1 0 |a Lilian M. Denzler  |e author 
700 1 0 |a Oliver E.C. Hood  |e author 
700 1 0 |a Andrew C.R. Martin  |e author 
245 0 0 |a Do antibody CDR loops change conformation upon binding? 
260 |b Taylor & Francis Group,   |c 2024-12-01T00:00:00Z. 
500 |a 10.1080/19420862.2024.2322533 
500 |a 1942-0870 
500 |a 1942-0862 
520 |a ABSTRACTAntibodies have increasingly been developed as drugs with over 100 now licensed in the US or EU. During development, it is often necessary to increase or reduce the affinity of an antibody and rational attempts to do so rely on having a structure of the antibody-antigen complex often obtained by modeling. The antigen-binding site consists primarily of six loops known as complementarity-determining regions (CDRs), and an open question has been whether these loops change their conformation when they bind to an antigen. Existing surveys of antibody-antigen complex structures have only examined CDR conformational change in case studies or small-scale surveys. With an increasing number of antibodies where both free and complexed structures have been deposited in the Protein Data Bank, a large-scale survey of CDR conformational change during binding is now possible. To this end, we built a dataset, AbAgDb, that currently includes 177 antibodies with high-quality CDRs, each of which has at least one bound and one unbound structure. We analyzed the conformational change of the Cα backbone of each CDR upon binding and found that, in most cases, the CDRs (other than CDR-H3) show minimal movement, while 70.6% and 87% of CDR-H3s showed global Cα RMSD ≤ 1.0Å and ≤ 2.0Å, respectively. We also compared bound CDR conformations with the conformational space of unbound CDRs and found most of the bound conformations are included in the unbound conformational space. In future, our results will contribute to developing insights into antibodies and new methods for modeling and docking. 
546 |a EN 
690 |a antibodies 
690 |a antibody structure 
690 |a complementarity determining regions 
690 |a CDRs 
690 |a CDR flexibility 
690 |a antibody binding 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Immunologic diseases. Allergy 
690 |a RC581-607 
655 7 |a article  |2 local 
786 0 |n mAbs, Vol 16, Iss 1 (2024) 
787 0 |n https://www.tandfonline.com/doi/10.1080/19420862.2024.2322533 
787 0 |n https://doaj.org/toc/1942-0862 
787 0 |n https://doaj.org/toc/1942-0870 
856 4 1 |u https://doaj.org/article/ea0ff2b1ed564d10a991b78706b3b6b9  |z Connect to this object online.